The role of the ERN EpiCARE Research Council is to support research conducted by EpiCARE members, with an aim to improve the quality and quantity of research within the network.
Specific goals include:
The EpiCARE Research Council includes EpiCARE’s Coordinator, 4 members of the EpiCARE Steering comittee, the ECET Chair, the Registry representative, the ePAG representatives, a representative of a current joint ERN/European research Initiatives (eg EJP RD, Human Brain Project that provide ressources to the network), the EpiCARE Research projects manager, the EpiCARE data manager and an ILAE representative.
The chair of EpiCARE’s Research Council is Helen Cross, deputy chair is Kees Braun. Members are Alexis Arzimanoglou, Sandor Beniczky, Ingmar Blümcke, Philippe Ryvlin, Renzo Guerrini, Rainer Surges, Eugen Trinka, Lieven Lagae, Rima Nabbout and Emilio Perucca.
An EpiCARE project will be defined as a project that is led by a number of EpiCARE members (at least 2) or from a single centre where data for a study is gathered from other EpiCARE HCP.
The project must be proposed to the research council prior to any funding application, and have undergone a quality check/peer review.
In order for ERN EpiCARE support to be given to a project, a project should be reviewed by the council. On submission, a reviewer will be nominated from the network and advice provided within 2 weeks. A letter will be provided by the Council Chair
The INNOMEM Open Calls have been extended until January 31st, 2023! Submit your application here to access the services offered by the project sustainable Open Innovation Test Bed to foster deployment and scale-up of innovative nano-enabled membranes and their derived products. Take a look at the INNOMEM catalogue to discover what services you can get from the project OITB: among them you will be able to access all of the PNO Consultants research and innovation services.
Want to discover more? Contact the OPEN CALL HELPDESK: opencall-helpdesk@innomem.eu. Learn more about INNOMEM visiting the website.
Deadline:2 February 2023
Indicative budget: 2 EUR million for a period of 5 years. However, an additional € 1 million can be made available to cover eligible “start-up” costs for researchers moving from a third country to the EU or an associated country and/or the purchase of major equipment and/or access to large facilities and/or other major experimental and field work costs.
Are you a scientist who wants to consolidate your independence by establishing a research team and continuing to develop a success career in Europe? The ERC Consolidator Grant could be for you. You can also apply if you have recently created an independent, excellent research team and want to strengthen it.
Who can apply?
Researchers of any nationality with 7-12 years of experience since completion of PhD (Extensions are possible under certain circumstances)
More information
Rare Epilepsy Partnership Award (1 year / $100,000) will support the development of necessary research tools, techniques, model systems, and data collection platforms to stimulate and accelerate research on rare epilepsies. Each award will be co-funded by CURE Epilepsy and one or more of the rare epilepsy advocacy groups (partners) identified in the Request For Proposals. Applications must focus on one or more of the specific rare epilepsies that are represented by each group as well as address CURE Epilepsy’s mission to cure epilepsy.
Registration Form Opens | Monday, January 16, 2023 |
Registration Form Submission Deadline | Wednesday, February 25, 2023 |
Selected Partners Informed | Wednesday, March 1, 2023 |
Request for Proposals Opens | Tuesday, May 30, 2023 |
Letter of Intent Deadline | Monday, June 26, 2023 |
Full Application Invitations | Monday, August 7, 2023 |
Full Application Deadline | Wednesday, September 13, 2023 |
Awardee Notification | December 2023-January 2024 |
Anticipated Award Start Date | Spring 2024 |
This European Institute of Innovation and Technology (EIT) call is open to both new organisations and existing partners from the pilot and second call for proposals.
Budget: Up to 16 projects will receive a maximum of €750 000: €350 000 for Phase 1 (May−Dec 2023) and €400 000 for Phase 2 (Jan−July 2024).
Deadline: 28.02.2023
Deadline:8 March 2023
Indicative budget: 77.5 EUR million
The SE action funds short-term international and inter-sectoral exchanges of staff members involved in research and innovation activities of participating organisations. The aim is to develop sustainable collaborative projects between different organisations from the academic and non-academic sectors (in particular SMEs), based in Europe and beyond. Exchanged staff benefit from new knowledge, skills and career development perspectives, while participating organisations increase their research and innovation capacities.
Who can apply for Staff Exchanges?
Staff Exchanges are open to international consortia of universities, research institutions, businesses, SMEs and other non-academic organisations. They need to include
What does the funding cover?
Staff Exchanges projects can last up to four years. The grant funds the mobility of seconded staff members from one month to one year. Staff involved should return to their sending organisations after the secondment, to pass on their knowledge.
Deadline: 15/03/2023
Indicative budget: EUR 10 000 000
Link: https://www.ihi.europa.eu/apply-funding/future-opportunities
Expected impacts to be achieved by this topic
The following impacts are expected:
Deadline: 15/03/2023
Indicative budget: between EUR 8 000 000 and EUR 10 000 000
The following impacts are expected:
Expected outcomes:
Deadline: 15/03/2023
Indicative budget: between EUR 8 000 000 and EUR 10 000 000
Link: https://www.ihi.europa.eu/apply-funding/future-opportunities
Expected impacts to be achieved by this topic
The following impacts are expected:
Expected outcomes
Deadline: 15/03/2023
Indicative budget: around EUR 20 000 000 to 30 000 000
Link: https://www.ihi.europa.eu/apply-funding/future-opportunities
Expected impacts to be achieved by this topic
Expected outcomes
EIC Accelerator Open has no predefined thematic priorities and is open to proposals in any field of technology or application. The EIC Accelerator supports the later stages of technology development as well as scale up. The technology component of your innovation must therefore have been tested and validated in a laboratory or other relevant environment (e.g. at least Technology Readiness Level 5 or higher). The EIC Accelerator looks to support companies where the EIC support will act as a catalyst to crowd in other investors necessary for the scale up of the innovation. The EIC Accelerator focuses on innovations building on scientific discovery or technological breakthroughs (‘deep tech’) and where significant funding is needed over a long timeframe before returns can be generated (‘patient capital’). Such innovations often struggle to attract financing because the risks and time period involved are too high. Funding and support from the EIC Accelerator is designed to enable such innovators to attract the full investment amounts needed for scale up in a shorter timeframe.
Deadline: 22 March 2023
Deadline for submission (single stage): April 13, 2023
Total budget: €25M
Budget per project: 4-6 M€
Objective
Deadline for submission (single stage): April 13, 2023
Budget: EUR 1.00 million
Proposals should address all of the following aspects:
– Develop a structured system of exchange of information between policy makers, funders, and other relevant bodies128 in order to establish synergies and avoid duplication of efforts.
The aim is to structure brain health research in Europe and pave the way for a possible future partnership.
-Develop a strategic research and innovation agenda, taking into account the efforts already undertaken by EU-supported actions. The strategic research and innovation agenda will identify a number of measurable, scientific-technological priorities and socio-economic objectives, supported by an appropriate analysis.
-Develop plans for a governance structure of a future partnership, as well as implementation modalities with long-term sustainability in mind, and under the leadership of an EU Member State or Associated Country.
-Ensure a broad geographical representation of European countries and plan for inclusion of all main related research initiatives, as well as key organisations and associations. In this way, the coordination action should reflect the ‘umbrella’ role of a future initiative that will structure brain health research in Europe, and make it more impactful.
– Consider international initiatives by engaging with global organisations, as well as with global initiatives and research organisations in the field.
– Elaborate on platforms and tools for use by the research community, including on how they can best complement, integrate with each other. In this context, infrastructures already developed at the European or national level that enable sharing of samples, quality data and advanced analytical tools should be included in the analysis. Reflections should also be made on how the future initiative can contribute to the development of the European Health Data Space.
Deadline for submission (single stage): April 13, 2023
Total budget: €35M
Budget per project: 8-10 M€
Objective
Deadline for submission (single stage): April 13, 2023
Total budget: €50M
Budget per project: 8-10 M€
Objective
-> To consolidate existing virtual twin models to move towards an integrated digital twin, with the goal of accelerating translational research towards the more cost-effective development of new health technologies
-Develop multi-scale, multi-organ, dynamic, interoperable and modular computer
capable of accurately simulating the pathophysiology of an individual patient, covering different anatomical scales.
– Implement proof-of-concept and feasibility studies in relevant end-user environments to validate the developed models.
– Involve relevant “Human and Social Sciences” expertise in the design and conduct of the
of the project.
Deadline:23 May 2023
Indicative budget: € 2.5 million for a period of 5 years. However, an additional € 1 million can be made available to cover eligible “start-up” costs for researchers moving from a third country to the EU or an associated country and/or the purchase of major equipment and/or access to large facilities and/or other major experimental and field work costs.
Are you an established, leading principal investigator who wants long-term funding to pursue a ground-breaking, high-risk project? The ERC Advanced Grant could be for you.
Who can apply?
Applicants for the ERC Advanced Grants – called Principal Investigators (PI) – are expected to be active researchers who have a track-record of significant research achievements in the last 10 years.
Deadline for submission (two stages)
Total budget: €30M
Budget per project: 8-10 M€
Objectives:
– To develop solutions that promote a healthy lifestyle solutions for children and adolescents to have a long-term impact by using digital technologies.
– Develop and integrate innovative, privacy preserving tools and technologies, such as (but not limited to) activity trackers, sensors, serious games, platforms and robotics, Massive Open Online Courses (MOOCs) in coordinated and integrated care models, to help children and adolescents lead healthy, active and social lifestyles, prevent diseases, as well as to better monitor and manage their physical, social and mental health.
– Involve SMEs, national and regional authorities, patient associations and all relevant stakeholders to improve the adoption of solutions in health systems
– Involve relevant “Human and Social Sciences” expertise in the design and conduct of the
of the project
Deadline for submission (two stages)
-September 19, 2023
-April 11, 2024
Total budget: €50M
Budget per project: 8- 12 M€
Objective
->To develop personalized strategies for prevention of non-communicable diseases (use of computational approaches, algorithms machine learning AI)
– Enable understanding of areas of unmet need in the prevention of non-communicable diseases, opportunity to mechanisms, management of disease progression and relapse. disease progression and relapse.
– Design new or improved and ambitious policy and intervention options
-Designing holistic approaches that include several of the following aspects: genetic predisposition
genetic predisposition, metagenomics, epigenomics, microbiome, metabolomics, sleep disorders, large cohorts, molecular profiling, impact of lack of activity, new predictive biomarker candidates,
nutrition and diet
Budget: EUR 50.00 million.
Deadline for submission (single stage): September 19,2023
The co-funded European Partnership on rare diseases should be implemented based on the priorities identified in the Strategic Research and Innovation Agenda and through a joint program of activities ranging from coordinating and funding transnational research to highly integrative and community-driven ‘in-house’ activities such as innovation strategies for the efficient exploitation of research results, EU clinical trial preparedness activities, optimization of research infrastructures and resources, including networking, training and dissemination activities. It should be structured along the following main objectives:
-Launch joint transnational calls for RD research and innovation priorities as defined in the Strategic Research and Innovation Agenda, resulting in financial support to third parties, based on the annual work plans;
– Develop a European Clinical Research Network to accelerate the clinical trial readiness of the RD research community in Europe, to improve the research and innovation potential of RD stakeholders and facilitate the cost-effective clinical development of new therapies;
– Develop and consolidate the capacity building of the RD data ecosystem by supporting the federated access/sharing of FAIR research data, information resources to ensure the effective and fast translation of the research results to safe and effective health innovations;
– Integrate basic, pre-clinical and clinical research to reduce the burden for people living with a rare disease.
– Support research in relevant medical fields and intervention areas (prevention, diagnosis, treatment), while improving the utilization of existing health technologies in clinical practice;
– Support the scientific work of the International Rare Disease Research Consortium.
Deadline for submission (two stages)
-September 19, 2023
-April 11, 2024
Total budget: €45M
Budget per project: 6- 7 M€
Scope: Effective, affordable and accessible healthcare for diverse population groups is challenging and complex. For example, specific needs underlie the delivery of effective preventive actions and therapeutic treatments to a rapidly growing elderly population, often presenting comorbidities and associated poly-pharmacy. The pediatric population, including children born preterm, has also its specific needs in specially adjusted therapeutics and early
Proposals should address most of the following:
-Compare the use of currently existing (pharmacological, non-pharmacological and technological) healthcare interventions in specific population groups (or selected subgroups). While there is no restriction on diseases or conditions, preference will be given to proposals focusing on interventions with high public health relevance.
-Ensure acceptability and sustainability of the healthcare intervention through early involvement of ‘end users’ (e.g. patients, care providers) in the design of the study (integrating patient valued outcomes) and, where possible, in the research process including implementation. Additionally, proposals should take into account the diversity of health systems in different regions of Europe to allow large-scale uptake.
-Consider involving HTA bodies in order to create synergies and accelerate the practical implementation of the results.
-Consider issues of particular relevance for the target populations, for example, multimorbidity, complex chronic conditions, poly-pharmacy, substance misuse, vaccine efficacy, compliance, age, gender specificities and diseases with high societal burden (including but not limited to e.g. musculoskeletal diseases and mental health disorders).
– For the chosen population, assess clinical and safety parameters, as well as health and socio-economic outcomes (e.g. quality of life, patient mortality, (co)morbidity, costs, and performance of the health system). Agreed core outcome sets (COS) should be used as endpoints in conditions where they already exist, in other cases, efforts should be made to agree on such COS. Consider using new instruments and methods for determining the burden of disease and for evaluating the effects of the interventions. Low cost innovations should also be considered.
Join us for the second edition of the EIC Summit which will take place on 7-8 December 2022 in Brussels. Do not miss the key European deep-tech innovation event of the year, bringing together start-ups, researchers, investors, policy makers and corporates.
The world’s largest brain research prize is Danish and is awarded by the Lundbeck Foundation. Each year, we award 10 million DKK (approx. 1,3 million€) to one or more brain researchers who have had a ground-breaking impact on brain research.
Nominations for 2023 are open
The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research, and winners may be of any nationality and work in any country around the globe. This broad perspective is reflected in the diverse fields of previous Brain Prize winners.
The Prize may be awarded to one or more scientists who have distinguished themselves through outstanding contributions to any field of neuroscience, from fundamental studies to research related to understanding and treatment of diseases of the brain and other parts of the nervous system.
Deadline for submission (two stages)
-September 19, 2023
-April 11, 2024
Total budget: €25M
Budget per project: 6- 7 M€
A number of medical conditions fail to be recognised and/or be correctly diagnosed in a significant proportion of patients. As a consequence they are inadequately treated and often can become a chronic burden for the patient. These medical conditions may be insufficiently researched even though they manifest with high prevalence166, 167. This topic excludes rare diseases.
Proposals should address all of the following aspects:
-Proposals should address the gaps in robust, scientific evidence for improved policies and practices to tackle such medical condition(s), and aim at identifying the pathophysiological mechanism(s) (e.g. genetic, cellular and molecular) and potential risk factors (e.g. psychological and environmental) of the medical condition(s) through basic, pre-clinical and/or clinical research. These efforts should underpin the development of diagnostics, therapeutics, and/or preventive strategies for the condition.
– Proposals should demonstrate that the medical condition(s) under study is/are insufficiently understood, inaccurately diagnosed or inadequately treated in a significant proportion of patients, and as such represent a high burden for patients and society. This could be through referencing key literature.
-Sex and gender aspects, age, ethnicity, socio-economic, lifestyle and behavioural factors should be taken into consideration. In addition, the emotional and societal long-term effects of these chronic disorders for the affected individuals should be addressed.
– Where applicable, the development of biomarkers and other technologies for diagnosis, monitoring in patients, and stratification of patient groups should be considered.
– Where applicable, the development of clinically relevant, (non-)human model systems that can complement clinical investigations should be considered.
– Exploitation of existing data, biobanks, registries and cohorts is expected, together with the generation of new (e.g. genomics, epigenomics, transcriptomics, proteomics) data.
The Global Innovation Fund (GIF) is currently inviting applications for its Grants program to support breakthrough solutions from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and catalyse meaningful change.
Deadline – Ongoing
The Global Innovation Fund invests in the development, rigorous testing, and scaling up of new products, services, business process, or policy reforms. Through its grants, GIF supports these breakthrough solutions from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and catalyse meaningful change.
If you are a non-profit and your innovation does not involve generating revenues from users or customers, a grant is likely to be most appropriate.
Stages of Funding
GIF has a staged funding approach, whereby the amount of funding available is tiered according to the level of maturity of your innovation and the activities proposed. The three tiers are:
Pilot – the innovation is at an early stage but you have a credible plan for how it can be developed and tested in a real-world setting. Funding of up to USD 230,000 is available to test core assumptions around operational, social, and financial viability.
Test and transition – the innovation has already shown promise of success at a small scale, and you have some information on your operational, social, and financial viability which you want to solidify before you scale. Funding of up to USD 2.3 million is available to support further growth and generate additional evidence on whether the innovation can achieve social impact and market viability, for commercial innovations.
Scale – the innovation has a strong evidence base and logistically credible plan for scaling to reach millions of people. Funding of up to USD 15 million is available to expand the reach of innovations with a view to reaching millions of people in the long term if successful.
What they Fund?
At GIF, they believe that innovation, by which they mean any solution that has potential to address an important development problem more effectively than existing approaches, can come from anyone, anywhere.
This means that they accept applications working in any sector in any developing country.
Any type of organisation may apply. This includes social enterprises, for-profit companies, non-profit organisations, government agencies, international organisations, and research institutions in any country. It is recommended that individual innovators, entrepreneurs, or researchers apply through an affiliated organisation.
Eligibility Criteria
Any type of organisation may apply. This includes social enterprises, for-profit companies, non-profit organisations, government agencies, international organisations, and research institutions in any country. It is recommended that individual innovators, entrepreneurs or researchers apply through an affiliated organisation.
Ineligible
GIF is open to innovations which meet their criteria in any sector or country. However, there are some activities they do not fund. These include:
A cost action is an interdisciplinary research network that brings researchers and innovators together to investigate a topic of their choice for 4 years. COST Actions are typically made up of researchers from academia, SMEs, public institutions and other relevant organisations or interested parties.
Open to all science and technology fields, including new and emerging fields; COST Actions offer an inclusive, pan-European environment for individuals of all levels of seniority to grow their professional research networks and boost their careers.
In today’s world it is essential for research to be interconnected, interdisciplinary, collaborative and data-intensive. By focusing on networking activities, COST Actions help to advance knowledge and strengthen the research and development sector, by creating networking opportunities for researchers to meet and discuss ideas, complex problems can be addressed in a targeted way, across a large geographical area.
Budget committed for projects funding : Projects are multinational but funding is national (contract is signed by national funding bodies) – more precision will be added
Deadlines: Two stages : 15th February 2023and 14th June 2023
Link: https://www.ejprarediseases.org/joint-transnational-call-2023/
Research proposals should cover at least one of the following areas:
It is possible to use cellular and animal models for validation of the new diagnostic approaches in the subtopics listed above where relevant.
Furthermore, additional elements need to be considered in the application:
You can sign up below to receive the EpiCARE Research Calls Newsletters, sent a few times a year, to inform about the new research calls:
Menu
Funding
The ERN EpiCARE was created in 2017 and is co-funded by the European Union.
EpiCARE © 2021 all rights reserved | Privacy Policy | Webdesign : Marc Chaperon
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-advertisement | 1 year | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Cookie | Duration | Description |
---|---|---|
YSC | session | This cookies is set by Youtube and is used to track the views of embedded videos. |
Cookie | Duration | Description |
---|---|---|
_ga | 2 years | This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors. |
Cookie | Duration | Description |
---|---|---|
IDE | 1 year 24 days | Used by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile. |
NID | 6 months | This cookie is used to a profile based on user's interest and display personalized ads to the users. |
test_cookie | 15 minutes | This cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies. |
VISITOR_INFO1_LIVE | 5 months 27 days | This cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website. |
Cookie | Duration | Description |
---|---|---|
_ga_K3WGJ1B9KB | 2 years | No description |
CONSENT | 16 years 7 months 7 days 16 hours 17 minutes | No description |